Diabetes mellitus is a widespread chronic metabolic disorder which affecting millions of individuals globally. A common yet complex and challenging condition like diabetes requires a safe yet effective treatment. While synthetic drugs have been the primary approach for managing diabetes, their limitations warrant exploration of alternative solutions. As the prevalence of diabetes is spirally incrising, research into alternative treatments and potential sources of antidiabetic compounds becomes increasingly crucial. In recent years, the potential of medicinal plants, including orchids, has gained significant attention due to their unique bioactive compounds. With 44 orchid species falling under 21 genera traditionally used for diabetes treatment, validated by experimental studies conducted on 27 genera encompassing 56 species, orchids represent a particularly promising avenue for discovering natural and sustainable alternatives to conventional therapies. Bioactive compounds such as gigantol, moscatilin, lusianthridin, and syringic acid were frequently associated with antihyperglycemic effects. Mechanisms included antioxidant activity, enzyme inhibition (α-amylase and α-glucosidase), insulin sensitisation, β-cell regeneration, and modulation of key signalling pathways (e.g., PI3K/Akt, AMPK). Several species also exhibited protective effects against diabetes-induced complications. Orchids have the potential to revolutionise diabetes treatment by offering natural, effective, and sustainable alternatives to conventional drugs. However, further research including and clinical trials is warranted for effective understanding of the therapeutic efficacy of orchids and translate them into practical treatments. With continued exploration and investment in this field, anti-diabetic orchids may become an integral part of our pharmaceutical arsenal against diabetes.